Literature DB >> 35677471

How to decrease systemic corticosteroids in pemphigus patients under rituximab.

Fabrizio Martora1, Vincenzo Picone1, Gabriella Fabbrocini1, Matteo Megna1.   

Abstract

Entities:  

Year:  2022        PMID: 35677471      PMCID: PMC9169508          DOI: 10.1002/hsr2.639

Source DB:  PubMed          Journal:  Health Sci Rep        ISSN: 2398-8835


× No keyword cloud information.
  14 in total

1.  Paradoxical worsening of pemphigus vulgaris following rituximab therapy.

Authors:  R J Feldman
Journal:  Br J Dermatol       Date:  2015-05-12       Impact factor: 9.302

Review 2.  Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment.

Authors:  Vito Di Lernia; Dahiana M Casanova; Mohamad Goldust; Cinzia Ricci
Journal:  Dermatol Pract Concept       Date:  2020-06-29

Review 3.  Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration.

Authors:  Hamidreza Mahmoudi; Soheil Tavakolpour; Kamran Balighi; Ali Salehi Farid; Ali Nili; Delnavaz Jan; Maryam Daneshpazhooh
Journal:  Dermatol Ther       Date:  2020-12-15       Impact factor: 2.851

4.  Paradoxical reaction to rituximab in patients with pemphigus: a report of 10 cases.

Authors:  Ali Nili; Soheil Tavakolpour; Hamidreza Mahmoudi; Pedram Noormohammadpour; Kamran Balighi; Maryam Daneshpazhooh
Journal:  Immunopharmacol Immunotoxicol       Date:  2020-01-27       Impact factor: 2.730

Review 5.  Iranian guideline for rituximab therapy in pemphigus patients.

Authors:  Maryam Daneshpazhooh; Kamran Balighi; Hamidreza Mahmoudi; Soheil Tavakolpour; Robabeh Abedini; Tahereh Soori; Amir-Houshang Ehsani; Maryam Ghiasi; Pedram Noormohammadpour; Narges Ghandi; Vahideh Lajevardi; Ali Sadeghinia; Maryam Nasimi; Arghavan Azizpour; Cheyda Chams-Davatchi
Journal:  Dermatol Ther       Date:  2019-07-24       Impact factor: 2.851

6.  An Unusual Case of Pemphigus Vulgaris.

Authors:  Laura Marano; Gabriella Fabbrocini; Giuseppe Monfrecola; Fabrizio Martora
Journal:  Skin Appendage Disord       Date:  2022-01-11

7.  Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.

Authors:  Claire Mignard; Maud Maho-Vaillant; Marie-Laure Golinski; Pierre Balayé; Catherine Prost-Squarcioni; Estelle Houivet; Sé Bastien Calbo; Bruno Labeille; Catherine Picard-Dahan; Maria Polina Konstantinou; Guillaume Chaby; Marie-Aleth Richard; Jean-David Bouaziz; Sophie Duvert-Lehembre; Emmanuel Delaporte; Philippe Bernard; Frédéric Caux; Marina Alexandre; Saskia Ingen-Housz-Oro; Pierre Vabres; Gaëlle Quereux; Alain Dupuy; Sébastien Debarbieux; Martine Avenel-Audran; Michel D'Incan; Christophe Bédane; Nathalie Bénéton; Denis Jullien; Nicolas Dupin; Laurent Misery; Laurent Machet; Marie Beylot-Barry; Olivier Dereure; Bruno Sassolas; Jacques Benichou; Pascal Joly; Vivien Hébert
Journal:  JAMA Dermatol       Date:  2020-05-01       Impact factor: 10.282

8.  Rituximab: A Review in Pemphigus Vulgaris.

Authors:  James E Frampton
Journal:  Am J Clin Dermatol       Date:  2019-12-14       Impact factor: 7.403

9.  Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison.

Authors:  Angelo Ruggiero; Gabriella Fabbrocini; Eleonora Cinelli; Matteo Megna
Journal:  J Am Acad Dermatol       Date:  2021-03-21       Impact factor: 11.527

10.  Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV).

Authors:  P Joly; B Horvath; Α Patsatsi; S Uzun; R Bech; S Beissert; R Bergman; P Bernard; L Borradori; M Caproni; F Caux; G Cianchini; M Daneshpazhooh; D De; M Dmochowski; K Drenovska; J Ehrchen; C Feliciani; M Goebeler; R Groves; C Guenther; S Hofmann; D Ioannides; C Kowalewski; R Ludwig; Y L Lim; B Marinovic; A V Marzano; J M Mascaró; D Mimouni; D F Murrell; C Pincelli; C P Squarcioni; M Sárdy; J Setterfield; E Sprecher; S Vassileva; K Wozniak; S Yayli; G Zambruno; D Zillikens; M Hertl; E Schmidt
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-08-24       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.